PRIOR AUTHORIZATION POLICY

POLICY: Lipodystrophy – Egrifta® (tesamorelin injection – EMD Serono)

TAC APPROVAL DATE: 04/10/2019

OVERVIEW
Egrifta is an analog of human growth hormone-releasing factor (GRF), indicated for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy.1-3 At this time, the long-term cardiovascular (CV) safety and potential long-term CV benefit are not established and careful consideration should be given to continue Egrifta in patients who do not show a clear efficacy response, as judged by the degree of reduction in visceral adipose tissue.1 Egrifta has a weight-neutral effect and is not indicated for weight loss management. There are no data supporting improved compliance with anti-retroviral therapies in HIV-positive patients who take Egrifta.

Disease Overview
Lipodystrophy is the change in body fat which affects some patients with HIV infection, either due to HIV infection or due to medication to treat HIV.5 Egrifta binds and stimulates human GRF receptors with similar potency as endogenous GRF. GRF stimulates the synthesis and pulsatile release of endogenous growth hormone (GH), which is both anabolic and lipolytic. GH exerts its effect by interacting with receptors on a variety of target cells resulting in the pharmacodynamic effect. A decrease in nocturnal secretion of GH and insulin-like growth factor 1 (IGF-1) is associated with increased visceral adipose tissue (VAT) in patients with HIV-associated lipodystrophy.2 Egrifta increases secretion of GH and has been shown to decrease VAT and spare subcutaneous adipose tissue (SAT).3-4 Egrifta is contraindicated in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or head trauma; patients with known hypersensitivity to Egrifta or mannitol; pregnant women; and in patients with an active malignancy.1 Any pre-existing malignancy should be inactive; patients should complete treatment prior to beginning Egrifta.

Other Therapies
There are no other therapies approved specifically for treatment of HIV-associated lipodystrophy and treatment options are limited.5-6 Administration of GH has demonstrated a significant decrease in VAT, but also a decrease in SAT, compared with placebo.7 Management strategies for lipodystrophy include: switching antiretroviral therapy, exercise and diet, cosmetic procedures (e.g., liposuction, facial fillers), and prevention of lipodystrophy by selection of regimens less likely to cause lipohypertrophy.6

Safety
Because the long-term CV safety and potential long-term CV benefit are not established, careful consideration should be given whether to continue Egrifta treatment in patients who do not show a clear efficacy response, as judged by the degree of reduction in visceral adipose tissue measured by waist circumference or CT scan. In the pivotal studies, efficacy of Egrifta was assessed at Week 26. Because Egrifta induces the release of endogenous GH (a known growth factor) and increases serum IGF-1, the benefits of treatment should be weighed against the increased risk of malignancies in HIV-positive patients. Since the effect of prolonged IGF-1 elevations on the development or progression
of malignancies is unknown, monitor IGF-1 levels closely during Egrifta therapy and consider discontinuation in patients with persistent elevations of IGF-1 levels (e.g., > 3 standard deviation scores [SDS]), especially if the patient has not experienced a robust response. Egrifta should be used with caution in patients who develop glucose intolerance or diabetes; discontinuation of therapy should be considered for patients who do not show a clear efficacy response.

**POLICY STATEMENT**

Prior authorization is recommended for prescription benefit coverage of Egrifta. Because of the specialized skills required for evaluation and diagnosis of patients treated with Egrifta as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Egrifta to be prescribed by or in consultation with a physician who specializes in the condition being treated. The FDA-approved indication is authorized for an initial 6-month duration (where 1 month is equal to 30 days), then for a 3-year approval duration for patients currently receiving Egrifta.

**Recommended Authorization Criteria**

Coverage of Egrifta is recommended in those who meet the following criteria:

**FDA-Approved Indications**

1. **Lipodystrophy in Human Immunodeficiency Virus (HIV)-Infected Patients.** Approve for the duration noted if the patient meets ONE of the following (A or B):
   A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following criteria (i, ii, and iii):
      i. The patient is an adult ≥ 18 years of age; AND
      ii. Egrifta is prescribed by or in consultation with an endocrinologist or a physician specializing in the treatment of human immunodeficiency virus (HIV) infection (e.g., infectious disease [ID], oncology); AND
      iii. Egrifta is prescribed for the reduction of excess abdominal fat.
   B) Patient is Currently Receiving Egrifta. Approve for 3 years if the patient has responded (e.g., reduction in visceral adipose tissue measured by waist circumference or computed tomography [CT] scan), as determined by the prescriber. The patient may not have a full response, but there should have been response to Egrifta.

**Conditions Not Recommended for Approval**

Egrifta has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.)

1. **Abdominal Obesity in Patients without Human Immunodeficiency Virus (HIV) Infection.** More data are needed. Egrifta has been studied in a very limited number patients who have abdominal obesity without HIV infection.° To be eligible for the published trial, patients were required to have a peak stimulated GH no higher than 9 µg/L on a standardized GH-releasing hormone (GHRH)-arginine stimulation test. Patients (n = 60) were randomized in a 1:1 ratio to
treatment with Egrifta 2 mg once daily (QD) or placebo. The primary endpoint was the change in VAT from baseline. Over 12 months (using last observation carried forward [LOCF]), VAT improved significantly in patients treated with Egrifta compared with placebo (net treatment effect vs. placebo: -35 [95% confidence interval {CI}: -58, -12]; P = 0.003). Treatment with Egrifta increased IGF-1 by 90%, decreased triglycerides by 20%, and decreased log C-reactive protein (CRP) by 24% compared with placebo. There was no effect on total cholesterol, high-density lipoprotein cholesterol (HDL-C), or low-density lipoprotein cholesterol (LDL-C) in the treatment groups.

2. **Human Immunodeficiency Virus (HIV)-Related Cachexia, Weight Loss, or Fat Distribution other than Lipodystrophy.** Egrifta has not been studied in these conditions.

3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

**REFERENCES**

1. Egrifta® injection [prescribing information]. Montreal, Quebec, Canada: Theratechnologies, Inc; July 2018.

**OTHER REFERENCES UTILIZED**


**HISTORY**

<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes*</th>
<th>TAC Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual revision</td>
<td>No criteria changes.</td>
<td>03/08/2017</td>
</tr>
<tr>
<td>Annual revision</td>
<td>No criteria changes.</td>
<td>04/04/2018</td>
</tr>
<tr>
<td>Annual revision</td>
<td>No criteria changes.</td>
<td>04/10/2019</td>
</tr>
</tbody>
</table>

TAC – Therapeutic Assessment Committee; * For a further summary of criteria changes, refer to respective TAC minutes available at: [http://esidepartments/sites/Dep043/Committees/TAC/Forms/AllItems.aspx](http://esidepartments/sites/Dep043/Committees/TAC/Forms/AllItems.aspx).